Phase 3 Readout
MANE: Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Eff
September 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 1, 2026
- Company
- Veradermics Incorporated (MANE)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Eff
- Indication
- Androgenetic Alopecia; AGA; Male Pattern Baldness